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Summary
Background.  —  Pulmonary  vein  isolation  (PVI)  takes  longer  when  using  a  patent  foramen  ovale
(PFO) compared  with  a  transseptal  puncture  in  paroxysmal  atrial  ﬁbrillation  (AF)  with  manual
catheter ablation.  To  our  knowledge,  no  data  exist  concerning  the  impact  of  a  PFO  on  AF  ablation
procedure  variables  when  using  a  remote  magnetic  navigation  (RMN)  system.
Aim. —  To  assess  the  impact  of  a  PFO  when  using  an  RMN  system  in  patients  requiring  AF  ablation.
Methods.  —  Between  December  2011  and  December  2012,  catheter  ablation  was  performed
remotely using  the  CARTO® 3  system  in  167  consecutive  patients  who  underwent  PVI  for  symp-
tomatic drug-refractory  AF.  The  radiofrequency  generator  was  set  to  a  ﬁxed  power  ≤  35  W.  The
primary endpoint  was  wide-area  circumferential  PVI  conﬁrmed  by  spiral  catheter  recording
during ablation  for  all  patients  and  including  additional  lesion  lines  (left  atrial  roof)  or  complex
fractionated  atrial  electrograms  for  persistent  AF.  Secondary  endpoints  included  procedural
data.
Abbreviations: AF, atrial ﬁbrillation; CHA2DS2-VASc score, Congestive heart failure, Hypertension, Age > 75 years (2 points), Diabetes
ellitus, Stroke or transient ischaemic attack (2 points), Vascular disease, Age 65—74 years and Sex category (female); CT, computed
omography; LA, left atrial/atrium; PFO, patent foramen ovale; PV, pulmonary vein; PVI, pulmonary vein isolation; RF, radiofrequency;
MN, remote magnetic navigation; TEE, transoesophageal echocardiography.
∗ Corresponding author. Service de Cardiologie, Hôpital Nord, Centre Hospitalier Universitaire de Saint-Étienne, 42055 Saint-Étienne cedex
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Results.  —  Mean  age  58  ±  10  years;  18%  women;  107  (64%)  patients  with  symptomatic  parox-
ysmal AF;  60  (36%)  with  persistent  AF;  CHA2DS2-VASc  score  1.2  ±  1.  The  PFO  presence  was
evidenced in  49/167  (29.3%)  patients  during  the  procedure  but  in  only  26/167  (16%)  by  transoe-
sophageal  echocardiography.  Median  procedure  time  2.5  ±  1  hours;  median  total  X-ray  exposure
time 14  ±  7  minutes;  transseptal  puncture  and  catheter  positioning  time  7.5  ±  5  minutes;
left atrium  electroanatomical  reconstruction  time  3  ±  2.3  minutes;  catheter  ablation  time
3 ±  3  minutes.  No  procedure  time  or  X-ray  exposure  differences  were  observed  between  patients
with or  without  a  PFO  during  magnetic  navigation  catheter  ablation.  X-ray  exposure  time  was
signiﬁcantly  reduced  using  a  PFO  compared  with  double  transseptal  puncture  access.
Conclusions.  —  A  PFO  does  not  affect  magnetic  navigation  during  AF  ablation;  procedure  times
and X-ray  exposure  were  similar.  Septal  catheter  probing  is  mandatory  to  limit  X-ray  exposure
and prevent  potential  complications.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  Il  a  été  démontré  que  la  durée  des  procédures  d’isolation  des  veines  pulmonaires
VPs était  plus  longue  lors  de  l’utilisation  d’un  foramen  ovale  perméable  (FOP)  comparée  à
l’utilisation  de  la  ponction  transeptale  dans  le  traitement  par  radiofréquence  (RF)  de  la  ﬁbril-
lation atriale  (FA)  paroxystique  par  la  technique  d’ablation  manuelle.  Il  n’y  a  pas,  à  notre
connaissance,  de  données  dans  la  littérature  sur  l’inﬂuence  du  FOP  sur  les  temps  ou  les  données
opératoires  lors  de  l’utilisation  d’un  robot  magnétique  (RM).
Objectif.  —  Cette  étude  prospective  a  cherché  à  évaluer  l’impact  de  l’utilisation  d’un  FOP  avec
un système  de  RM  sur  les  procédures  de  RF  de  FA  en  comparaison  avec  la  double  ponction
transeptale.
Méthodes. — Entre  décembre  2011  et  décembre  2012,  167  patients  consécutifs  ont  bénéﬁcié
d’un traitement  par  RF  par  technique  du  RM.  L’objectif  principal  était  l’isolement  électrique
des VPs  conﬁrmé  par  la  technique  du  lassos  et  la  réalisation  de  lignes  complémentaires  et/ou
l’ablation de  potentiels  fractionnés  en  cas  de  FA  persistante.
Résultats.  — Cent  soixante  sept  patients  ont  été  inclus  (58  ±  10  ans  ;  18  %  de  femmes),  dont
107 FA  paroxystiques  (64  %)  et  60  FA  persistantes  (36  %).  Un  FOP  était  présent  chez  49/167
(29,3 %)  au  cours  de  la  procédure  mais  seulement  26/167  (16  %)  ont  été  détectés  par  échogra-
phie transoesophagienne.  Le  temps  médian  de  procédure  était  de  2,5  ±  1  heures  et  la  médiane
d’exposition  aux  rayons  X  était  de  14  ±  7  minutes  (ponction  transeptale  et  positionnement  des
cathéters 7,5  ±  5  min,  reconstruction  électro-anatomique  de  l’oreillette  gauche  3  ±  2  min,  et
temps d’ablation  robotisé  3  ±  2  min).  Aucune  différence  de  temps  opératoire  ou  d’exposition
aux rayons  X  n’a  été  observé  entre  les  patients  avec  présence  d’un  FOP  et  les  patients  avec
double ponction  transeptale.
Conclusions.  —  La  présence  et  l’utilisation  d’un  FOP  n’ont  pas  d’impact  sur  les  temps  opéra-
toires et  sur  la  durée  d’exposition  aux  rayons  X  lors  de  l’utilisation  de  la  technique  par  robot
magnétique  au  cours  des  ablations  de  ﬁbrillation  atriale.  La  présence  d’un  FOP  permet  de
réduire de  manière  signiﬁcative  le  temps  d’exposition  aux  rayons  X  en  comparaison  avec  la
double ponction  transeptale.
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Background
Over  the  last  few  years,  radiofrequency  (RF)  therapy  has
played  a  decisive  role  in  the  treatment  of  complex  arrhyth-
mias  and,  more  particularly,  atrial  ﬁbrillation  (AF)  [1—8].
This  technology  requires  experienced  operators,  but  X-ray
exposure  and  complications  remain  too  high  [2,4,6,7]. The
current  trend  favors  technology  that  is  similar  to  or  more
effective  than  manual  RF  techniques,  but  safer.  The  remote
magnetic  navigation  (RMN)  system  appears  to  be  an  inno-
vative  technology  with  a  very  favorable  beneﬁt/risk  ratio
for  both  the  patient  and  operator,  in  combination  with
three-dimensional  non-ﬂuoroscopic  navigation  [9—15].  Dur-
ing  manual  paroxysmal  AF  RF,  pulmonary  vein  isolation  (PVI)
u
c
ws  droits  réservés.
ppeared  to  take  longer  when  using  a  patent  foramen  ovale
PFO)  compared  with  a  transseptal  puncture,  but  proce-
ural  variables  were  not  inﬂuenced  by  the  PFO  presence
uring  linear  left  atrial  (LA)  RF  [16—18]. The  use  of  a  ﬂexi-
le  magnetic  catheter  has  increased  the  safety  of  complex
rocedures  such  as  RF  ablation  considerably;  the  risk  of
erforation  was  shown  to  be  almost  zero  and  was  more
ue  to  the  softness  of  the  catheter  than  to  the  constant
orce  applied  to  the  tissue,  which  did  not  exceed  15—20  g
9,11,13,15]. However,  the  softness  of  the  catheter  and  the
FO  orientation  could  be  inconvenient  compared  with  man-
al  transseptal  puncture.  To  our  knowledge,  no  data  exist
oncerning  the  impact  of  a  PFO  on  AF  ablation  procedures
hen  using  a  remote  magnetic  navigation  (RMN)  system.
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This  prospective  study  aimed  to  assess  the  impact  of  PFO
n  AF  ablation  procedures  when  using  a  RMN  system.
ethods
atheter  ablation  was  performed  remotely  using  the  Niobe®
I  RMN  system  (Stereotaxis  Inc.,  St.  Louis,  MO,  USA)
ombined  with  a  new  three-dimensional  non-ﬂuoroscopic
avigation  system  (CARTO® 3  system;  Biosense  Webster,  CA,
SA)  in  167  consecutive  patients  who  underwent  pulmonary
ein  (PV)  disconnection  for  symptomatic  drug-refractory  AF.
etection of a patent foramen ovale [17]
ransoesophageal  echocardiography  (TEE)  was  performed  in
ll  patients  within  the  48  hours  before  the  ablation  proce-
ure  to  rule  out  the  presence  of  an  atrial  thrombus  and
o  detect  the  presence  of  a  PFO.  Brieﬂy,  the  TEE  trans-
erse  four-chamber  and  longitudinal  cavae  views  were  used
o  detect  the  presence  of  a  PFO.  Doppler  color  ﬂow  was
sed  ﬁrst.  Right-sided  contrast  injections  using  10  mL  of
anually  agitated  saline  solution  or  dextrose  solution  were
hen  rapidly  injected  into  a  peripheral  brachial  vein  to  gen-
rate  echogenic  microbubbles.  In  the  presence  of  a PFO,
hese  microbubbles  crossed  the  interatrial  septum  from
he  right  atrium  to  the  left  atrium  (LA).  Transient  ele-
ations  of  right  atrial  pressure  produced  by  coughing  or
alsalva  manoeuvres  were  used  to  facilitate  the  passage
f  microbubbles.  During  the  ablation  procedure,  catheter
anipulation  in  the  region  of  the  septum  was  systematically
sed  to  probe  for  a  PFO  before  transseptal  puncture  in  all
ases.
lectrophysiological procedures
ll  patients  received  anticoagulation  therapy  with  vitamin
 antagonists  for  at  least  2  months  prior  to  the  procedure
target  international  normalized  ratio,  2:3)  and  therapeutic
nticoagulation  was  maintained  with  intravenous  or  low-
olecular-weight  heparin  following  vitamin  K  antagonist
iscontinuation  starting  3  days  before  the  intervention.  TEE
as  performed  within  the  48  hours  before  the  procedure  to
xclude  LA  thrombus.  Vitamin  K  antagonists  were  resumed
he  day  after  the  procedure  and  effective  anticoagulation
as  maintained  with  heparin  until  the  international  normal-
zed  ratio  was  >  2.0.  Surface  electrocardiograms  and  bipolar
ndocardial  electrograms  (ﬁltered  from  30  to  500  Hz)  were
ontinuously  monitored  and  stored  on  a  computer-based
igital  ampliﬁer/recorder  system.  A  deﬂectable  quadripo-
ar  catheter  (5  mm  interelectrode  spacing;  Xtrem®; ELA
edical,  Montrouge,  France)  was  positioned  in  the  coro-
ary  sinus  for  pacing  and  recording.  The  LA  was  accessed
y  a  PFO,  when  present,  or  by  transseptal  double  punc-
ure.  A  guidewire  was  introduced  into  the  LA  using  an  8
 long  sheath.  The  sheath  was  perfused  during  the  pro-
edure  with  heparinized  solution  (3000  U  of  heparin  in
00  mL  of  sodium  chloride  0.9%  at  a  rate  of  150  mL/hour). multipolar  deﬂectable  catheter  (LASSO®; Biosense  Web-
ter,  Diamond  Bar,  CA,  USA)  was  inserted  through  the
ong  sheath  to  map  the  PV  ostia  for  all  ablation  proce-
ures.
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RF  ablation  was  performed  using  a  3.5  mm  open
rrigated-tip  magnetic  ablation  catheter  (NAVISTAR® RMT
HERMOCOOL®;  Biosense  Webster,  Diamond  Bar,  CA,  USA).
he  catheter  was  advanced  into  the  LA  through  a  sec-
nd  transseptal  puncture  or  the  same  PFO.  The  venous
heath  was  then  withdrawn  in  the  right  atrium  and  continu-
usly  perfused.  Following  transseptal  puncture,  intravenous
nfractionated  heparin  was  administered  as  a  bolus  (7500
),  and  additional  boluses  were  given  throughout  the
rocedure  to  maintain  an  activated  clotting  time  of  at
east  300  seconds.  Activated  clotting  time  was  deter-
ined  30  minutes  after  the  transseptal  puncture  and  every
0  minutes  thereafter.  When  the  activated  clotting  time
as  <  300  seconds,  an  additional  bolus  of  2500  U  was  admin-
stered.  Deep  sedation  was  achieved  using  intravenous
albuphine  and  midalzolam.
adiofrequency catheter ablation procedures
egardless  of  the  study  group,  the  ablation  endpoints  were
VI,  deﬁned  as  complete  elimination  or  dissociation  of  pul-
onary  potentials  validated  with  a  circumferential  mapping
atheter  in  all  cases  (paroxysmal  and  persistent  AF),  as  well
s  the  creation  of  linear  lesions  interconnecting  the  upper
V  ostia  (rooﬂine).
RF was  applied  using  an  open  irrigated-tip  catheter  with
 power  output  ≤  35  W  close  to  the  PV  ostia  and  30  W
or  the  rooﬂine  or  while  creating  coronary  sinus  discon-
ection.  Irrigation  with  sodium  chloride  0.9%  at  a  rate  of
0—35  mL/min  was  employed  to  maintain  a tip  temperature
f  <  43 ◦C.
emote magnetic navigation system and
ARTO® 3 system features
he  RMN  system  (Niobe  II;  Stereotaxis  Inc.,  St.  Louis,  MO,
SA)  is  a  technological  platform  that  uses  a  steerable  mag-
etic  ﬁeld  to  remotely  guide  a  supple  catheter  inside  the
eart  [9,11,13]. The  CARTO® 3  system  used  allows  for  real-
ime  Advanced  Catheter  LocationTM and  visualization  of
oth  ablation  and  circular  mapping  catheters  (NAVISTAR  and
ASSO  catheters).  The  catheter  location  display  is  identi-
al  to  that  of  the  ﬂuoroscopic  view.  The  CARTO® 3  system
ombines  electromagnetic  technology  (as  in  the  CARTO®
P  system)  with  new  advanced  catheter  location  technol-
gy  that  enables  visualization  of  multiple  catheters  without
uoroscopy.  Both  technologies  have  been  described  fully
lsewhere  [9,11,13,15].
easurements: procedural and ﬂuoroscopy
ariables
he  following  variables  were  recorded  for  all  patients
nd  compared  within  study  groups:  total  procedure  dura-
ion  (skin  to  skin;  minutes);  total  X-ray  exposure  (minutes
nd  Gy/cm2),  from  needle  insertion  to  ultimate  catheter
emoval;  skin  to  catheter  positioning  X-ray  exposure  (min-
tes  and  Gy/cm2),  from  femoral  access  to  the  end  of
atheter  positioning  in  the  LA,  including  double  transseptal
ccess;  LA  electroanatomical  mapping  X-ray  exposure  (min-
tes  and  Gy/cm2),  from  catheter  positioning  in  the  LA  to  the
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Table  1  Patient  characteristics  (n  = 167).
Characteristic
Age  (years)  58  ±  9
Women  18
Hypertension  37
Diabetes  6.6
Tobacco 21.5
Hypercholesterolemia  20.3
AF  type
Paroxysmal 64
Persistent  36
CHA2DS2-VASc  score  1.2  ±  1
AF  duration  (months)a 36  ±  48
Structural  heart  disease  27.5
History  of  atrial  ﬂutter  29.3
LVEF  (%)  60  ±  9
TLAD  (mm)  43  ±  7
LA  surface  (cm2)  23  ±  6
Total  procedure  time  (minutes)  2.7  ±  0.7
Total  X-ray  exposure  (minutes)  15  ±  6
Number  of  AAs  testeda 2.3  ±  1
Data are mean ± standard deviation or percentage. AA: antiar-
rhythmic agents; AF: atrial ﬁbrillation; AFL: atrial ﬂutter;
CHA2DS2-VASc: Congestive heart failure, Hypertension, Age > 75
years (2 points), Diabetes mellitus, Stroke or transient ischaemic
attack (2 points), Vascular disease, Age 65—74 years and Sex
category (female); LA: left atrium; LVEF: left ventricular
ejection fraction; TLAD: transversal left atrial diameter.
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creation  of  a  satisfactory  electroanatomical  reconstruction
compared  with  the  LA  computed  tomography  scan;  ablation
X-ray  exposure  (minutes  and  Gy/cm2),  from  the  ﬁrst  to  the
last  RF  delivery.
Endpoints
The  primary  endpoint  was  wide-area  circumferential  PVI,
conﬁrmed  by  spiral  catheter  recording  during  ablation  in
all  patients.  PVI  was  deﬁned  as  abolition  or  dissociation
of  activities  in  all  of  the  PVs.  PV  potentials  and  far-ﬁeld
potentials  were  distinguished  with  pacing  technique  from
the  LA,  LA  appendage  or  coronary  sinus,  using  the  abla-
tion  or  the  quadripolar  catheter.  An  additional  lesion  line
(LA  roof)  or  coronary  sinus  defragmentation  or  complex
fractionated  electrogram  lesions  for  persistent  AF  could
be  performed.  Secondary  endpoints  included  procedural
data,  complications  and  freedom  from  atrial  tachycardia/
AF.
Follow-up
Patients  were  routinely  hospitalized  for  3  days  postpro-
cedure  and  a  blanking  period  of  2  months  was  applied.
The  blanking  period  was  deﬁned  as  a  period  during  which
early  recurrences  were  considered  a  transient  phenomenon
rather  than  a  procedure  failure.  Antiarrhythmic  medica-
tion  was  maintained  for  6  months  and  then  discontinued
in  patients  with  paroxysmal  AF,  but  maintained  in  those
with  persistent  AF.  Vitamin  K  antagonists  were  contin-
ued,  with  consideration  for  the  Congestive  heart  failure,
Hypertension,  Age  >  75  years  [2  points],  Diabetes  mellitus,
Stroke  or  transient  ischaemic  attack  [2  points],  Vascular
disease,  Age  65—74  years  and  Sex  category  [female]  score
(CHA2DS2-VASc).  Success  was  deﬁned  as  the  absence  of  any
documented  arrhythmia  or  symptoms  suggestive  of  arrhyth-
mia  recurrences.  Twenty-four-hour  Holter  monitoring  was
performed  each  time  the  patient  experienced  palpitations.
Patients  were  followed  every  6  months  by  means  of  a  clin-
ical  interview.  A  redo  procedure  was  permitted  >  6  months
after  the  index  procedure,  if  the  patient  so  wished.
Statistical analysis
All  clinical  variables  were  assessed  at  the  time  of  the
hospitalization  and  procedure.  Continuous  variables  are
presented  as  mean  ±  standard  deviation  or  median  with
interquartile,  as  appropriate.  Categorical  variables  are
expressed  as  percentages.  Statistical  signiﬁcance  was
assessed  using  the  unpaired  Student’s  t  test  or  the
Mann—Whitney  test,  if  necessary.  Categorical  variables,
expressed  as  numbers  or  percentages,  were  analyzed  with
the  chi-square  test  or  Fisher’s  exact  test.  All  tests  were
two-tailed  and  a  P  value  <  0.05  was  considered  statistically
signiﬁcant.  Cumulative  event  rates  (i.e.  the  occurrence  of
subsequent  arrhythmia)  were  calculated  according  to  the
Kaplan—Meier  method.  All  analyses  were  performed  using
StatView® 5.0  software  (Abacus  Concept,  Berkeley,  CA,
USA).
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aseline population characteristics
aseline  clinical  data  are  summarized  in  Table  1.  In  total,
67  patients  were  prospectively  included,  with  the  follow-
ng  patient  characteristics:  mean  age  58  ±  10  years;  18%
omen;  107  (64%)  with  symptomatic  paroxysmal  AF;  60
36%)  with  persistent  AF;  CHA2DS2-VASc  score  1.2  ±  1;  mean
A  diameter  43  ±  0.7  mm;  27.5%  with  structural  heart  dis-
ase.  The  percentage  of  circumferential  PVI,  conﬁrmed  by
piral  catheter  recording  during  ablation,  was  97%.
resence of a patent foramen ovale
mong  the  167  patients,  a  PFO  was  found  in  26/167  (16%)
atients  by  TEE  and  in  23  additional  patients  (total  49/167;
9.3%)  by  catheter  probing  (Tables  2—4).  All  patients
ith  a  PFO  detected  by  TEE  also  had  the  PFO  identiﬁed
y  catheter  manipulation.  All  patients  had  transthoracic
chocardiography  the  day  after  the  procedure;  one  of
he  patients  with  a  double  transseptal  puncture  had  a
ericardial  effusion  without  hemodynamic  consequences
nd  without  pericardiocentesis  —  this  patient  was  treated
edically.  When  LA  access  was  carried  out  via  a  PFO,  pro-
edure  duration  (2.6  ±  0.6  vs  2.7  ±  0.7  hours;  P  =  0.3)  and
otal  RMN  X-ray  exposure  for  catheter  ablation  navigation
3  ±  2  vs  3.8  ±  3 minutes;  P  = 0.2)  were  similar  between  the
roups.
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Table  2  Comparison  between  patent  foramen  ovale  and  double  transseptal  puncture  groups  in  the  overall  population.
Characteristic  PFO  (n  =  49)  Double  transseptal  puncture  (n  =  118)  P
Age  (years)  57  ±  10  59  ±  10  0.4
Women  9  (18)  21  (18)  0.9
Structural  heart  disease  15  (31)  33  (28)  0.6
Persistent  AF 15 (31) 30  (26)  0.6
CHA2DS2-VASc  score 1.2  ±  1.1 1.1  ±  1 0.6
AF  duration  (months)a 52  ±  38 55 ±  45 0.6
LVEF  (%)  61  ±  9  60  ±  9  0.9
TLAD  (mm)  40.3  ±  0.7  40.3  ±  0.7  0.8
Number  of  AAs  tested  2.3  ±  1  2.1  ±  1  0.8
Procedure  time  (minutes)a 2.6  ±  0.6  2.7  ±  0.7  0.3
X-ray  exposure  (minutes;
Gy/cm2)a
Total  11.5  ±  5;  45  ±  30  16.5  ±  6;  70  ±  44  <  0.0001
Dual  transseptal  puncture
and  catheter  positioning
5.5 ±  3.2;  21  ±  18  9.7  ±  5.4;  51  ±  93  <  0.0001
LA  electroanatomical
reconstruction
3 ±  1.5;  11  ±  11  3.4  ±  2;  14  ±  20  0.2
Catheter  ablation  3  ±  2;  13  ±  13  3.8  ±  3;  25  ±  23  0.2
Data are mean ± standard deviation or number (%). AA: antiarrhythmic agents; AF: atrial ﬁbrillation; CHA2DS2-VASc: Congestive heart
failure, Hypertension, Age > 75 years (2 points), Diabetes mellitus, Stroke or transient ischaemic attack (2 points), Vascular disease,
Age 65—74 years and Sex category (female); LA: left atrium; LVEF: left ventricular ejection fraction; PFO: patent foramen ovale; TLAD:
transversal left atrial diameter.
a Median ± interquartile.
Table  3  Comparison  between  patent  foramen  ovale  and  double  transseptal  puncture  groups  in  the  paroxysmal  atrial
ﬁbrillation  population.
Characteristic  PFO  (n  =  34)  Double  transseptal  puncture  (n  =  71)  P
Procedure  time  (minutes)  2.6  ±  0.7  2.7  ±  0.7  0.8
X-ray  exposure  (minutes;  Gy/cm2)
Total  12  ±  0.5;  42  ±  31  17  ±  7;  70  ±  41  0.0006
Dual  transseptal  puncture
and  catheter  positioning
6 ±  3.5;  21  ±  19  10  ±  6;  51  ±  40  0.1
LA  electroanatomical
reconstruction
2.8 ±  1.5;  8  ±  7 3  ±  2;  11  ±  10  0.3
Catheter  ablation  3  ±  2;  1.2  ±  1.4  4  ±  3;  3 ±  9  0.3
Data are median ± interquartile. LA: left atrium; PFO: patent foramen ovale.
Table  4  Comparison  between  the  patent  foramen  ovale  and  double  transseptal  puncture  groups  in  the  persistent  atrial
ﬁbrillation  population.
Characteristic  PFO  (n  =  15)  Double  transseptal  puncture  (n  =  47)  P
Procedure  time  (minutes)  2.6  ±  0.5  2.9  ±  0.7  0.1
X-ray  exposure  (minutes;  Gy/cm2)
Total  11  ±  4;  51  ±  26  16  ±  6;  71  ±  49  0.14
Dual  transseptal  puncture
and  catheter  positioning
4.6 ±  3;  23  ±  15  9  ±  4;  52  ±  76  0.2
LA  electroanatomical
reconstruction
3.4 ±  1.7;  19  ±  15  3.7  ±  2.3;  17  ±  29  0.6
Catheter  ablation 3  ±  2;  12  ±  10  3.6  ±  4;  17  ±  22  0.4
Data are median ± interquartile. LA: left atrium; PFO: patent foramen ovale.
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Total ﬂuoroscopy (median ± interquartile)
The  procedure  time  was  2.5  ±  1  hours.  X-ray  exposure
was  as  follows:  total,  14  ±  7  minutes  (49  ±  36  Gy/cm2);
dual  transseptal  puncture  and  catheter  positioning,
7.5  ±  5  minutes  (25  ±  22  Gy/cm2);  LA  electroanatomical
reconstruction,  3  ±  2.3  minutes  (10  ±  9  Gy/cm2);  catheter
ablation,  3  ±  4  minutes  (14  ±  4  Gy/cm2).  Procedure  times
and  X-ray  exposure  were  similar  even  if  AF  was  paroxysmal
or  persistent.  Moreover,  PFO  access  reduces  X-ray  exposure
signiﬁcantly  compared  with  dual  septal  puncture.
Complications
Five  hours  after  the  procedure,  a  67-year-old  woman  with
a  PFO  presented  a  cerebral  hemorrhage  requiring  neuro-
surgical  emergency  revision.  The  postoperative  period  was
unfortunately  complicated  by  a  deﬁnitive  right  hemiplegic
procedure-related  deﬁcit.  No  tamponade  was  observed  and
no  char  on  the  catheter  tip  was  noticed  upon  catheter
removal.
Discussion
Major ﬁndings
This  prospective  study  found  that  a  PFO  presence  does  not
affect  magnetic  navigation  during  AF  ablation.  Procedure
times  and  X-ray  exposure  were  similar  even  if  AF  was  parox-
ysmal  or  persistent.
We  also  found  that  septal  catheter  probing  detected  PFO
access  in  twice  as  many  patients  compared  with  TEE.  In
order  to  limit  X-ray  exposure  and  transseptal  risk,  the  pro-
bing  test  seems  to  be  appropriate.  This  point  may  have  a
signiﬁcant  impact  in  patients  who  have  redo  procedures.
Patent foramen ovale detection
A  PFO  is  an  integral  part  of  the  normal  fetal  circulation  and
anatomical  closure  occurs  later  in  infancy  in  the  majority  of
the  population  [19].  Contrast  echocardiography  has  demon-
strated  that  anatomical  closure  is  incomplete  in  one  in  every
four  adults  [19].  Knecht  et  al.  ﬁrst  reported  the  method
of  septal  probing  for  passing  a  catheter  through  a  PFO  to
achieve  LA  access,  particularly  in  patients  requiring  AF  abla-
tion  procedures  [17].  Thus,  probing  the  septum  may  provide
an  alternative  strategy  that  avoids  the  complications  of  the
transseptal  procedure.  We  found  the  presence  of  a  PFO  by
TEE  in  13%  of  patients  when  using  a  brachial  injection  of  agi-
tated  saline  or  dextrose  solution,  whereas  catheter  probing
allowed  access  in  24%  of  patients  [17].  Several  causes  have
been  suggested,  such  as  the  lack  of  sensitivity  of  brachial
contrast  injection  compared  with  vena  cava  injection  dur-
ing  TEE  and  a  tiny  ﬁbrous  closure  that  can  be  opened  by
the  catheter  contact  force  [16—18].  Our  study  conﬁrmed
these  results,  with  29%  of  mechanical  passage  detected  with
catheter  probing  and  only  16%  with  the  TEE  method.  The
autopsy-derived  prevalence  of  a  probe-patent  PFO  is  about
27%,  conﬁrming  the  results  from  the  study  by  Knecht  et  al.
and  our  own  results  [20].  Accordingly,  approximately  25%  of
patients  referred  for  AF  ablation  do  not  require  transsep-
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al  puncture  if  PFO  use  does  not  affect  the  procedure  per
e.  Moreover,  our  results  demonstrated  that  PFO  use  sig-
iﬁcantly  reduced  total  X-ray  exposure  by  avoiding  dual
ransseptal  puncture,  without  affecting  RMN.
mpact of patent foramen ovale presence on
emote magnetic navigation atrial ﬁbrillation
rocedures
ne  of  the  principal  advantages  reported  in  the  literature
ith  RMN  is  the  highly  signiﬁcant  decrease  in  X-ray  exposure
9,11,13]. This  observation  may  appear  trivial  when  consid-
ring  the  short-term  effects  for  the  patients,  but  in  cases
here  multiple  interventions  using  radiation  are  performed,
his  could  represent  a very  signiﬁcant  reduction  in  total  X-
ay  exposure  time  for  the  physician  and  for  the  patient  [15].
his  observation  is  even  more  pertinent  for  electrophysiol-
gists,  whose  multidisciplinary  activities  might  include  the
mplantation  of  resynchronization  devices  and  the  ablation
f  complex  arrhythmias,  with  obvious  long-term  beneﬁts
9,21—24].  The  amplitude  of  the  reduction  in  X-ray  expo-
ure  was  evaluated  to  be  50%  on  average  [25,26]. Similar
esults  were  published  by  Kim  et  al.,  reporting  a  mean
eduction  of  29  minutes  in  comparison  with  the  conventional
ethod  [27]. Despite  lacking  a control  group,  we  recently
howed  that  this  new  technology  allows  AF  procedures  to
e  performed  with  a  very  short  X-ray  exposure  (median
 ±  4  minutes;  10  Gy/cm2),  which  includes  LA  acquisition
ap  and  AF  ablation  times  [28].  Consequently,  the  presence
f  a  PFO  should  reduce  X-ray  exposure  more,  but  only  if
he  magnetic  catheter  navigation  is  not  distorted.  Indeed,
exible  magnetic  catheters  have  considerably  increased  the
afety  of  complex  procedures  such  as  RF  ablation  in  AF,  but
atheter  softness  might  be  a  limitation  when  using  a  PFO.
ndeed,  certain  theoretical  advantages  (such  as  catheter
tability,  access  to  difﬁcult  zones  such  as  the  right  inferior
V,  quality  of  the  practiced  lines  and  lesion  homogeneity)
ppear  to  favor  RMN,  but  a narrow  and  anterior-superior
FO  passage  might  affect  ablation  procedure  times.  Thus,
necht  et  al.  found  that  a  trans-PFO  might  increase  the  difﬁ-
ulty  of  paroxysmal  AF  manual  catheter  ablation,  mainly  due
o  the  more  anterosuperior  LA  access,  resulting  in  less  accu-
ate  catheter  positioning  regarding  the  posterior  anatomical
osition  of  the  PVs  [17]. Several  hypotheses  have  been  con-
idered,  such  as  a  more  anterior-superior  access  and  a  less
irect  approach  to  the  PVs,  particularly  the  inferior  PVs
17]. A  larger  septal  hole  might  be  also  a disadvantage,
eading  to  a  lack  of  support,  again  reducing  catheter  sta-
ility  [16—18]. The  same  group  proved  that  the  PFO  did  not
ffect  the  manual  RF  procedures  in  patients  with  persistent
F  [18].  To  our  knowledge,  no  data  have  been  published
oncerning  PFO  and  RMN.  Our  results  demonstrated  that
sing  a  PFO  with  RMN  does  not  affect  procedure  times  but
educes  signiﬁcantly  X-ray  exposure  compared  with  dual
eptal  puncture.  Furthermore,  the  PFO  access  appears  to  be
ore  secure;  for  example,  in  our  study,  the  only  case  of  peri-
ardial  effusion  was  in  the  dual  transseptal  puncture  group.
onsequently,  the  advantages  of  the  catheter  softness  per-
ist  and  the  navigation  is  performed  equally  well  with  a
FO  compared  with  the  supposed  double  transseptal  access
eneﬁt.
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linical implications
hile  catheter  ablation  to  isolate  PVs  has  become  the  ther-
py  of  choice  for  managing  drug-refractory  symptomatic  AF,
t  is  still  considered  to  be  a  second-line  treatment  accord-
ng  to  the  latest  guidelines  [10].  Even  experienced  operators
an  ﬁnd  achieving  a  successful  outcome  without  unnecessary
dverse  events  very  challenging  when  using  these  proce-
ures  [10].  Given  this  context,  our  study  has  shown  that
MN  is  feasible  via  a  PFO  with  very  low  X-ray  exposure  time
nd  no  additional  complications  in  both  paroxysmal  and  per-
istent  AF.  Although  the  transseptal  puncture  technique  has
een  shown  to  be  safe  in  the  majority  of  cases,  this  pro-
edure  can  result  in  life-threatening  complications,  such
s  cardiac  tamponade,  systemic  emboli  and  aortic  perfo-
ation  in  0.74—1.3%  of  cases  [16].  The  trans-PFO  method,
s  demonstrated  by  the  Bordeaux  group,  can  be  an  alterna-
ive  to  the  transseptal  puncture  technique  and  might  avoid
etrimental  complications,  especially  during  difﬁcult  pro-
edures  [16].  Our  study  found  that  its  application  with  RMN
oes  not  increase  difﬁculty  with  the  navigation  system  or
uccess  rate  and  can  be  used  systematically.  Additionally,
his  study  demonstrates  that  there  is  no  particular  advan-
age  with  a  double  transseptal  puncture  compared  with  a
FO  for  RMN.  Moreover,  PFO  access  reduces  X-ray  exposure
igniﬁcantly  compared  with  dual  septal  puncture.  This  point
ay  have  a  signiﬁcant  impact  in  patients  who  have  redo
rocedures.
tudy limitations
he  analysis  of  the  persistent  AF  group  was  limited  by  the
umber  of  patients  included  (n  =  62)  and  further  studies  will
ertainly  be  needed  to  conﬁrm  these  results.  The  PFO  rate
lose  to  30%  seems  to  be  overestimated,  mainly  because  the
perator  was  aware  of  the  preprocedural  TEE  and  all  known
FOs  were  sought  assiduously  at  the  time  of  the  procedure.
oreover,  we  cannot  exclude  that  the  catheter  itself  can
eopen  the  PFO  hole  (tiny  ﬁbrous  closure).  However,  detec-
ion  of  a  PFO  using  TEE  and  the  Valsalva  manoeuvre  probably
ed  to  an  underestimation  of  the  rate  of  PFO  (16%).  Indeed,
he  Valsalva  manoeuvre  is  not  easy  to  perform  adequately
hen  you  have  been  sedated  and  you  have  the  echocardiog-
aphy  probe  in  the  esophagus.  The  standard  technique  for
etecting  PFO  is  really  transthoracic  echocardiography  and
 strong  Valsalva  manoeuvre.
onclusions
 PFO  does  not  affect  magnetic  navigation  during  AF  abla-
ion;  procedure  times  and  X-ray  exposure  were  similar.
eptal  catheter  probing  is  mandatory  to  limit  X-ray  expo-
ure.
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